Vertex Pharmaceuticals (VRTX) Non-Current Deffered Revenue (2009 - 2017)

Vertex Pharmaceuticals' Non-Current Deffered Revenue history runs 9 years deep, the most recent figure standing at $1.7 million for Q4 2017.

• In Q4 2017, Non-Current Deffered Revenue fell 73.97% year-over-year to $1.7 million; the TTM figure through Dec 2017 stood at $1.7 million (down 73.97% YoY), while the FY2017 annual figure was $1.7 million, down 73.97% from the prior year.
• Non-Current Deffered Revenue for Q4 2017 stood at $1.7 million, down from $2.9 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $90.3 million in Q1 2013, with the low at $1.7 million in Q4 2017.
• The 5-year median for Non-Current Deffered Revenue is $19.3 million (2015), against an average of $28.1 million.
• The sharpest annual moves came in 2013 and 2017: Non-Current Deffered Revenue decreased 22.28% in 2013, then sank 73.97% in 2017.
• Vertex Pharmaceuticals' Non-Current Deffered Revenue stood at $49.5 million in 2013, then plunged by 43.78% to $27.8 million in 2014, then tumbled by 65.07% to $9.7 million in 2015, then slumped by 31.73% to $6.6 million in 2016, then sank by 73.97% to $1.7 million in 2017.
• Business Quant data shows VRTX's Non-Current Deffered Revenue at $1.7 million in Q4 2017, $2.9 million in Q3 2017, and $4.2 million in Q2 2017.